TSE:VRX - Valeant Pharmaceuticals Intl Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous CloseC$30.46
Today's RangeC$30.27 - C$31.18
52-Week RangeC$14.01 - C$36.02
Volume557,537 shs
Average Volume1.38 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Valeant Pharmaceuticals International, Inc. operates as a multinational, specialty pharmaceutical, and medical device company that develops, manufactures, and markets a range of pharmaceuticals, over-the-counter (OTC) products, and medical devices. The company operates through three segments: Bausch + Lomb/International, Branded Rx, and U.S. Diversified Products. The Bausch + Lomb/International segment provides pharmaceutical products, OTC products, and medical device products, primarily consist of Bausch + Lomb products, with a focus on the vision care, surgical, consumer, and ophthalmology Rx products in the United States; and pharmaceutical products, generic pharmaceutical products, OTC products, medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia and New Zealand, Latin America, Africa, and the Middle East. The Branded Rx segment sells gastrointestinal and dermatological products in the United States. The U.S. Diversified Products segment offers pharmaceutical products, OTC products, and medical device products in the areas of neurology and certain other therapeutic classes, including aesthetics. The company was founded in 1983 and is headquartered in Laval, Canada.

Receive VRX News and Ratings via Email

Sign-up to receive the latest news and ratings for VRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange TSE
Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
Current SymbolTSE:VRX
Previous Symbol
CUSIPN/A
Phone+1-514-7446792

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding SharesN/A
Market CapC$0.00
OptionableOptionable

Valeant Pharmaceuticals Intl (TSE:VRX) Frequently Asked Questions

What is Valeant Pharmaceuticals Intl's stock symbol?

Valeant Pharmaceuticals Intl trades on the Toronto Stock Exchange (TSX) under the ticker symbol "VRX."

What price target have analysts set for VRX?

1 brokers have issued twelve-month price objectives for Valeant Pharmaceuticals Intl's stock. Their forecasts range from C$25.00 to C$25.00. On average, they anticipate Valeant Pharmaceuticals Intl's share price to reach C$25.00 in the next year. View Analyst Price Targets for Valeant Pharmaceuticals Intl.

What is the consensus analysts' recommendation for Valeant Pharmaceuticals Intl?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Valeant Pharmaceuticals Intl in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Valeant Pharmaceuticals Intl.

Has Valeant Pharmaceuticals Intl been receiving favorable news coverage?

News headlines about VRX stock have trended somewhat positive on Sunday, according to InfoTrie. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Valeant Pharmaceuticals Intl earned a coverage optimism score of 1.9 on InfoTrie's scale. They also assigned news headlines about the specialty pharmaceutical company a news buzz of 3.0 out of 10, indicating that recent media coverage is unlikely to have an effect on the company's share price in the next several days.

Who are some of Valeant Pharmaceuticals Intl's key competitors?

Who are Valeant Pharmaceuticals Intl's key executives?

Valeant Pharmaceuticals Intl's management team includes the folowing people:
  • Mr. Joseph C. Papa, CEO & Chairman (Age 63)
  • Mr. Paul S. Herendeen, Exec. VP & CFO (Age 62)
  • Ms. Christina M. Ackermann, Exec. VP & Gen. Counsel (Age 53)
  • Mr. Thomas J. Appio, Exec. VP & Group Chairman of International (Age 56)
  • Mr. William D. Humphries, Exec. VP & Group Chairman of Dermatology (Age 52)

How do I buy shares of Valeant Pharmaceuticals Intl?

Shares of VRX and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Valeant Pharmaceuticals Intl's official website?

The official website for Valeant Pharmaceuticals Intl is http://www.valeant.com/.

How can I contact Valeant Pharmaceuticals Intl?

Valeant Pharmaceuticals Intl's mailing address is 2150 Saint-Elzear Blvd W, LAVAL, QC H7L 4A8, Canada. The specialty pharmaceutical company can be reached via phone at +1-514-7446792.


MarketBeat Community Rating for Valeant Pharmaceuticals Intl (TSE VRX)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  309 (Vote Outperform)
Underperform Votes:  341 (Vote Underperform)
Total Votes:  650
MarketBeat's community ratings are surveys of what our community members think about Valeant Pharmaceuticals Intl and other stocks. Vote "Outperform" if you believe VRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/9/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel